Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice

Alagöz, Neşe; Tellioglu, Adem; Bektasoglu, Damla; Yaşar, Tekin; Paşaoğlu, Işıl; Altan, Ayse Cigdem; Solmaz, Banu; Başarır, Berna

doi:10.1089/jop.2020.0032

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By extending the trabecular meshwork, and Schlemm's canal, the parasympathomimetics cause smooth muscle cells in the ciliary body to contract, enhancing the outflow of aqueous humor [78]. The most well-known member of this class of antiglaucoma medications that can lower IOP is pilocarpine [81].…”

Section: Parasympathomimeticsmentioning

confidence: 99%

Current Measures Against Ophthalmic Complications of Diabetes Mellitus-a Short Review

et al. 2021

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder, whose prevalence is predicted to rise shortly. The present review focuses on the various ocular complications associated with DM, and the various ophthalmic formulation approaches developed to treat the same. Diabetic macular edema (DME), diabetic retinopathy, cataracts, and glaucoma are some of the major vision-threatening complications linked to DM. The ocular route of drug delivery has undergone several advancements in recent decades, the introduction of various novel drug delivery systems (DDS), various modifications in the existing formulation approaches, development of custom-designed personalized medications, being some of the major developments introduced in the field of ocular drug delivery. Due to the application of state-of-the-art technologies in the field of innovations related to ocular DDS, patients have been immensely benefited by the current modes of ocular treatment imparting fewer side effects, enhanced penetration, sustained drug effect, and so on. The present review includes and emphasizes the gradual development that has occurred from the conventional ophthalmic dosage forms to the currently reported novel ocular drug delivery approaches along with the related clinical research works.

show abstract

Section: Parasympathomimeticsmentioning

confidence: 99%